CD274 and lymphoma: Clinically, the effective rate of PD-1/PD-L1 inhibitors is approximately 80% in lymphoma, 60% in high microsatellite instability tumors, and 10% ~ 30% in other common solid tumors 52, thereby limiting its wide-scale applicability.